✅ Model Answer:
• Diagnosis: Papillary necrosis secondary to sickle cell nephropathy.
• Evidence: Sickle cell disease, gross hematuria, flank pain, CT urography showing medullary clefts and sloughed papillae.
• Next step: Hydration, pain control (avoid NSAIDs), treat sickle cell crisis if present. If severe hematuria, consider ε-aminocaproic acid (EACA) or desmopressin (DDAVP). Monitor renal function and BP.

✅ Model Answer:
• Mechanism: Sickle cell hemoglobin polymerizes in the hypoxic, hypertonic, acidic environment of the renal medulla → vaso-occlusion → ischemia → infarction of renal papillae.
• Result: Necrosis of the renal papillae → sloughing of papillae → gross hematuria, flank pain, and passage of necrotic tissue in urine (papillary fragments).
• Risk factors: Sickle cell anemia (HbSS), sickle cell trait (HbAS – rare), dehydration, acidosis, infection, NSAID use.
• Complications: Renal papillary necrosis can lead to chronic kidney disease, concentrating defect (hyposthenuria), and increased risk of urinary tract infections.

✅ Model Answer:
• Classic features:
- Gross hematuria: Often the presenting symptom (may be unilateral).
- Flank pain: Unilateral or bilateral (due to renal infarction).
- Fever: Due to tissue necrosis or secondary infection.
- Dysuria, frequency (if infection).
- Passage of tissue fragments in urine (papillary fragments – can be seen on microscopy).
• Other features:
- Renal concentrating defect: Hyposthenuria (inability to concentrate urine) – early manifestation.
- Hypertension: May develop later.
- Chronic kidney disease: Progressive renal impairment.
- Urinary tract infections: Increased risk due to stasis and tissue damage.

✅ Model Answer:
• Imaging:
- CT urography: Gold standard – shows medullary clefts, sloughed papillae, "ring sign" (contrast around necrotic papillae).
- Renal ultrasound: May show medullary echogenicity, hydronephrosis (if obstruction).
- Intravenous pyelography (IVP): Historically used, now largely replaced by CT.
• Laboratory tests:
- Urinalysis: Gross or microscopic hematuria, pyuria (if infection), tissue fragments.
- Serum creatinine: May be elevated (acute kidney injury).
- Urine culture: To rule out infection.
- Urine concentrating ability: Specific gravity (hyposthenuria).
• Other: Sickle cell workup (if not already diagnosed): Hb electrophoresis.

✅ Model Answer:
• General measures:
- Aggressive hydration: IV fluids to maintain urine output and prevent sickling.
- Pain control: Opioids (e.g., morphine) – avoid NSAIDs (increase risk of bleeding and AKI).
- Treat underlying sickle cell crisis: If indicated (exchange transfusion, oxygen).
- Antibiotics: If infection is present (urine culture-guided).
• For severe hematuria:
- ε-aminocaproic acid (EACA): 75-100 mg/kg IV then 100-200 mg/kg/day continuous infusion (antifibrinolytic).
- Desmopressin (DDAVP): 0.3 mcg/kg IV (may reduce bleeding).
• Avoid: NSAIDs, dehydration, contrast nephropathy (if CT with contrast – ensure hydration).
• Supportive: Monitor renal function, BP, and urine output.

✅ Model Answer:
• Renal:
- Chronic kidney disease (CKD): Progressive renal impairment due to loss of functional nephrons.
- Renal papillary necrosis can lead to:
- Hydronephrosis: If sloughed papillae obstruct the ureter.
- Urinary tract infections: Due to urinary stasis and tissue damage.
- Renal concentrating defect: Hyposthenuria (inability to concentrate urine) → polyuria, nocturia.
- Hypertension: Due to renal ischemia and renin release.
• Other:
- Anemia: Due to chronic blood loss from hematuria.
- Growth failure: If CKD is severe.
- End-stage kidney disease (ESKD): In severe cases.

✅ Model Answer:
• Prognosis:
- Variable: Depends on the severity of sickle cell disease and frequency of crises.
- Renal concentrating defect: Usually irreversible.
- Papillary necrosis: Can recur with future sickle cell crises.
- CKD: Develops in 30-40% of adults with sickle cell disease.
- ESKD: Occurs in 5-10% of patients, usually in adulthood.
• Long-term follow-up:
- Monitor BP: Annually.
- Monitor proteinuria: Spot urine protein/creatinine ratio annually.
- Monitor creatinine/eGFR: Annually.
- Renal ultrasound: Every 1-2 years (for nephrocalcinosis, hydronephrosis).
- Hydroxyurea: Can reduce sickle cell crises and may slow progression of nephropathy.
- ACE inhibitors: If proteinuria develops.
- Avoid: Dehydration, NSAIDs, contrast agents.

✅ Model Answer:
• ε-aminocaproic acid (EACA): An antifibrinolytic agent that inhibits plasminogen activation, thereby stabilizing clots.
• Indication: Severe, persistent hematuria in sickle cell disease (when conservative measures fail).
• Mechanism: Prevents breakdown of fibrin clots in the renal pelvis, allowing hemostasis.
• Dose: 75-100 mg/kg IV loading dose, then 100-200 mg/kg/day continuous infusion (or 50-75 mg/kg every 6 hours).
• Duration: Usually 24-48 hours (until hematuria resolves).
• Side effects: Intravascular thrombosis (rare), hypotension, nausea, vomiting.
• Contraindications: Active thrombosis, DIC, disseminated malignancy.
• Alternatives: Desmopressin (DDAVP), which increases factor VIII and VWF levels.